TechSeeker Profile

Amgen Inc (AKA: Applied Molecular Genetics Inc)
Profile last edited on: 4/3/2022

Therapeutic products in supportive of cancer care, inflammation, nephrology and bone disease
TS Type
Major Corp
Not Small
Year Founded
Last Involved Year

Key People / Management

  Robert A Bradway -- Chairman, CEO & President

  Kevin W Sharer -- CEO

  Beatrice Cookson -- Director

  Brad W Crawford -- Director Licensing

  Scott Foraker -- Vice-president of licensi

  Shelley George -- Director Medical Affairs

  Peter H Griffith -- Exec. VP & CFO

  Jeremy Grunstein -- Associate Manager Licensi

  Randal Hassler --

  Claes W Hornstrand -- Director, Licensing, Sale

  Lewis K Lee --

  Tae Weon Lee --

  Larry Lin -- Associate Director, Licen

  Gladys A Nunez --

  Steven M Odre -- Sr. Vice President,

  R Perlmutter --

  Joseph Phillips --

  Linda M Pullan -- Director, Licensing

  David M Reese -- Exec. VP of R&D

  Erwin Ruhland --

  Esteban Santos -- Exec. VP of Operations

  Aaron J Schuchart -- Associate Director Licens

  Craig Schulz --

  Beth C Seidenberg --

  Geoff Slaff --

  Will Suvari -- Mgr.Marketing

  Dave Tillett --

  Albert Tsai -- Product Manager

  Paul Tsang --

  Kapil Vashistha -- BAI Manager Amgen Inc.

Location Information

One Amgen Center Drive
Thousand Oaks, CA 91320
   (805) 447-1000

Public Profile

Originally formed as Applied Molecular Genetics Inc, Amgen is now the largest of the biotechs, Amgen makes and markets therapeutic products for hematopoiesis (blood cell production), inflammation and autoimmunity, neurobiology, and soft-tissue repair. Already Publicy traded (1983), before their first SBIR award in 1986, Amgen's SBIR participation was limited and very early in the firms development - but nonetheless an important part of the start-up effort. The Corporation's key products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company's principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company's products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. It is useful also to note that of the NINE acquisitions so far, FIVE have been themselves SBIR involved.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Publicly Traded
Stock Info
Received SBIR $$